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Introduction
Austrian Syndrome is a rare complication of disseminated Streptococcus 
pneumoniae infection, consisting of pneumonia, meningitis, and 
endocarditis. 
Case Description
A 64 year old male with a history of alcohol and tobacco abuse presented 
with a fever of 101.5° F and acute change in mental status. According to 
his wife, he had been coughing for 3 weeks. Physical examination noted left 
ptosis and mydriasis, decreased RUL breath sounds, and an irregular pulse. 
Chest x-ray confirmed RUL pneumonia and EKG showed atrial flutter. CT 
brain was negative for mass or herniation. Lumbar puncture was performed 
and blood cultures were obtained. Vancomycin and ceftriaxone were then 
initiated. He was intubated and transferred to the intensive care unit. 
The cerebrospinal fluid and urine antigen tests were positive for 
Streptococcus pneumonia, so dexamethasone was started as pneumococcal 
meningitis treatment. Subsequently, the blood cultures were noted to be 
positive for gram positive cocci. Transesophageal echocardiogram was 
ordered to rule out endocarditis, and it showed probable mitral valve 
vegetation. Later, multiple cranial nerve palsies and a brain empyema 
developed, with thoracic and lumbar emboli resulting in quadriplegia. The 
patient expired on hospital day 25. 
Discussion
The lungs are the usual portal of entry for pneumococcus leading to 
pneumonia. There are many predisposing risk factors for invasive 
pneumococcal disease. Alcoholism is one of the strongest risk factors 
for pneumococcal endocarditis. The complications of Austrian syndrome 
include systemic embolization, valve perforation and abscess formation. 
Transesophageal echocardiography is preferred to transthoracic 
echocardiography in detecting vegetations. Treatment begins empirically 
with vancomycin and cefotaxime or ceftriaxone until penicillin sensitivity 
is resulted. Surgical treatment of the valvular lesions is required in the 
majority of cases. Austrian syndrome is associated with a 24-63% mortality 
rate, which makes early diagnosis and appropriate treatment critical. The 
significance of pneumococcal antimicrobial resistance and the role of 
vaccination will also be discussed. 
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Austrian triad was named after Dr. Robert Austrian in 1957, who presented 8 cases that were associated with aortic valve 
rupture and 6 of which died. 
The first to relate this triad was an Austrian pathologist, Dr. Heschl in 1862, and subsequently by Sir William Osler in 1881 
(the year that pneumococcus was discovered).
Lung is the usual portal of entry for Pneumococcus (82%). Once encountered, both humoral and cellular responses are 
initiated to fight the infection. 
Invasive pneumococcal disease (IPD) is defined by the isolation of pneumococci from normally sterile sites (pleural fluid, 
blood and CSF). There are risk factors (local and systemic) that have been identified for IPD. 
Once bacteremia is sustained, pneumococcus can seed various organs. Meningitis is a common complication, occurring 
in 59.5% of the cases in one study.  
In the preantibiotic era, pneumococcus was responsible for 15-20% of endocarditis. Since the advent of penicillin in the 
early 1940s, pneumococcal endocarditis has been seen in 3% of patients with infectious endocarditis (IE). 
Many reports have linked pneumococcal endocarditis with alcoholism, transforming Osler’s triad into a tetrad.






Streptococcus pneumonia has a predilection for the aortic valve (74%). However, a pre-existing valvulopathy is not the 
rule in pneumococcal endocarditis. 
Echocardiography plays an important role in the diagnosis of IE: 
	 	 1)	 	TTE	is	a	noninvasive,	rapid	procedure	with	excellent	specificity	for	vegetations	(98%),	but	has	poor	sensitivity	(<60%).		
Besides,	TTE	alone	cannot	exclude	important	aspects	of	IE,	including	fistulae,	leaflet	perforation,	infection	on	prosthetic	
valves,	and	periannular	abscess.





In acute bacterial meningitis or endocarditis, recommendations are to start patient empirically on cefotaxime/ceftriaxone 
and vancomycin, until penicillin sensitivity is obtained. If the pneumococcus is resistant to cefotaxime (MIC >2 µg/ml), 
then a vancomycin and rifampin combination should be used. 
Corticosteroid is beneficial in treating pneumococcal meningitis patients. It reduces the inflammatory response, increases 
cerebral perfusion, and improves the adults’ outcome.
The clinical course of pneumococcal endocarditis is usually acute and aggressive. Local (peri-valvular abscesses, or 
perforated valves), and systemic (uncontrolled infection, and multiple emboli) complications frequently occur despite 
adequate antibiotic usage. As a result, surgical treatment of the valvular lesions is required in the majority of cases. 








Significance of Pneumococcal Antimicrobial Resistance
Currently, 15 to 30% of S. pneumoniae worldwide are multidrug-resistant (MDR). 
Despite increase in antimicrobial resistance worldwide over the past few decades, mortality rates for IPD have not 
increased. 





Given the above confounding factors, dissecting out the impact of antimicrobial resistance on clinical outcomes is 
difficult, if not impossible. 
Vaccination and its Importance
In the United States, about 39,750 cases of IPD and 4,000 deaths occur annually. 
The clinical spectrum from colonization to IPD depends on the pneumococcal capsular serotype. Currently, 94 capsular 
serotypes have been identified. 
Six serotypes (i.e., 4, 6B, 9V, 14, 19F, and 23F) account for >80% of IPD in children and >50% of IPD in adults in the 
United States. They also account for the majority of IPD in Europe.
Since the introduction of the PCV7 (4, 6B, 9V, 14, 18C, 19F, 23F), the rate of IPD due to PCV7 serotypes has declined 
significantly in many countries. In the US, it decreased from 64% of invasive and 50% of noninvasive isolates in 1999–
2000 to 3.8% and 4.2%, respectively, in 2010–2011. 
The PCV7 also has indirect (herd) effects that have led to decreased incidence of vaccine serotypes disease in 
unvaccinated children and adults.  
However, there have been reports of an increase in non-PCV7 serotypes, especially 19A. This phenomenon is termed 
‘replacement’.
PCV13 adds pneumococcal serotypes 1, 3, 5, 6A, 7F, and 19A to PCV7’s serotypes to provide coverage for over 85% of 
epidemiologically significant pneumococcal serotypes in the United States and throughout the world.
Austrian Triad and Vaccination
Reports of pneumococcal endocarditis often failed to provide adequate data on either the infecting pneumococcal 
serotype or patients’ vaccination histories. 
Among the limited data we have, Aronin et el showed that the most common capsular serotypes that were identified 
causing Austrian triad were 12, 1, and 8. Hence, PCV 13 could potentially prevent a significant number of Austrian 
syndrome cases.
Future Prospects
The development of effective conserved pneumococcal protein vaccines (CPPV) that would not target the polysaccharide 
capsule are currently in trials. These may prevent pneumococcal disease and carriage without resulting in the selective 
pressure that is thought to drive serotype replacement.
